Lumida
/ARVN
⌘K
Arvinas Inc

Arvinas Inc

ARVN
$8.01USD↓-0.25%-0.02 today

MARKET CAP

516.8M

P/E (TTM)

—

FWD P/E

—

DAY RANGE

$8 – $8

52W RANGE

$6
$15

AI Summary

Stalk
StalkMedium

ARVN is in an early Stage 1 consolidation following a terminal decline, with a Bullish Pivot Point pattern signaling failure of downside control and structural repair toward a higher equilibrium. The medium-term bias is bullish within this emerging base, but short-term conditions are extended near the upper boundary and RSI is overbought. Execution should be deferred, stalking for a pullback and absorption around the rising 9/20 EMA zone near prior resistance.

  • ↑FDA approval of Veppanu treats ESR1 mutant ER+ breast cancer, marking first PROTAC therapeutic approved.
  • ↑Q1’26 cash balance of $614.9M funds operations through mid-2028, underpinning ongoing trials and pipeline expansion.
  • ↓Q1’26 revenue fell 91.7% YoY to $15.6M, driven by reduced Pfizer collaboration income.
Full analysis →
Insider Trades32 trades
Date↓SideTicker↕Insider↕Role↕Shares↕Price↕Mkt Cap↕52W High↕52W Low↕Value↕% Chg↕Rule↕AI View↕
Jun 24, 2026SellARVNAndrew SaikChief Financial Officer5,696$8.16$516.8M-44.80%+32.29%$46.5K-2.95%—Stalk
Jun 17, 2026SellARVNAngela M CacaceChief Scientific Officer2,576$7.60$516.8M-44.80%+32.29%$19.6K-1.41%—Stalk
May 21, 2026SellARVNRandy TeelPresident and CEO2,209$9.04$516.8M-44.80%+32.29%$20.0K-0.77%—Stalk
May 11, 2026SellARVNDavid K LoomisVP, Chief Accounting Officer1,919$9.94$516.8M-44.80%+32.29%$19.1K-4.56%—Stalk
May 11, 2026SellARVNRandy TeelPresident and CEO9,657$9.94$516.8M-44.80%+32.29%$96.0K-3.25%—Stalk
May 11, 2026SellARVNAngela M CacaceChief Scientific Officer9,657$9.94$516.8M-44.80%+32.29%$96.0K-5.01%—Stalk
May 11, 2026SellARVNNoah BerkowitzChief Medical Officer11,108$9.94$516.8M-44.80%+32.29%$110.4K-5.49%—Stalk
May 11, 2026SellARVNAndrew SaikChief Financial Officer11,139$9.94$516.8M-44.80%+32.29%$110.7K-5.45%—Stalk
Mar 18, 2026SellARVNNoah BerkowitzChief Medical Officer6,435$11.10$516.8M-44.80%+32.29%$71.4K-3.08%—Stalk
Feb 23, 2026SellARVNDavid K LoomisChief Accounting Officer1,108$12.16$516.8M-44.80%+32.29%$13.5K-3.60%—Stalk
Feb 23, 2026SellARVNAngela M CacaceChief Scientific Officer3,609$12.16$516.8M-44.80%+32.29%$43.9K-1.20%—Stalk
Feb 23, 2026SellARVNRandy TeelPresident and CEO4,786$12.16$516.8M-44.80%+32.29%$58.2K-1.55%—Stalk
Feb 13, 2026SellARVNDavid K LoomisChief Accounting Officer1,016$11.89$516.8M-44.80%+32.29%$12.1K-3.19%—Stalk
Feb 13, 2026SellARVNRandy TeelPresident and CEO4,403$11.89$516.8M-44.80%+32.29%$52.4K-2.77%—Stalk
Feb 13, 2026SellARVNAngela M CacaceChief Scientific Officer4,592$11.89$516.8M-44.80%+32.29%$54.6K-2.95%—Stalk
Feb 13, 2026SellARVNAndrew SaikChief Financial Officer5,134$11.89$516.8M-44.80%+32.29%$61.0K-3.12%—Stalk
Feb 13, 2026SellARVNNoah BerkowitzChief Medical Officer5,685$11.89$516.8M-44.80%+32.29%$67.6K-3.35%—Stalk
Nov 7, 2025SellARVNDavid K LoomisChief Accounting Officer230$9.89$516.8M-44.80%+32.29%$2.3K-0.72%—Stalk
Jun 24, 2025SellARVNAndrew SaikChief Financial Officer5,700$7.61$516.8M-44.80%+32.29%$43.4K-3.35%—Stalk
Jun 17, 2025SellARVNAngela M CacaceChief Scientific Officer2,583$7.49$516.8M-44.80%+32.29%$19.3K-1.65%—Stalk
Mar 18, 2025SellARVNNoah BerkowitzChief Medical Officer8,658$8.59$516.8M-44.80%+32.29%$74.4K-7.30%—Stalk
Feb 24, 2025SellARVNDavid K LoomisChief Accounting Officer1,214$16.75$516.8M-44.80%+32.29%$20.3K-6.05%—Stalk
Feb 24, 2025SellARVNAngela M CacaceChief Scientific Officer4,207$16.70$516.8M-44.80%+32.29%$70.2K-2.11%—Stalk
Feb 24, 2025SellARVNIan TaylorPresident, R&D9,020$16.71$516.8M-44.80%+32.29%$150.8K-2.74%—Stalk
Feb 24, 2025SellARVNJohn G HoustonPresident and CEO31,338$16.72$516.8M-44.80%+32.29%$523.9K-1.33%—Stalk
Feb 23, 2024SellARVNRonald PeckChief Medical Officer1,699$47.05$516.8M-44.80%+32.29%$79.9K-1.33%—Stalk
Feb 23, 2024SellARVNIan TaylorChief Scientific Officer1,701$47.05$516.8M-44.80%+32.29%$80.0K-0.82%—Stalk
Feb 23, 2024SellARVNSean A CassidyChief Financial Officer1,702$47.05$516.8M-44.80%+32.29%$80.1K-0.93%—Stalk
Feb 23, 2024SellARVNJohn G HoustonPresident and CEO5,196$47.05$516.8M-44.80%+32.29%$244.5K-0.42%—Stalk
Jan 4, 2024BuyARVNIan TaylorChief Scientific Officer8,252$16.00$516.8M-44.80%+32.29%$132.0K+7.22%—Stalk
Nov 8, 2023SellARVNDavid K LoomisChief Accounting Officer460$22.39$516.8M-44.80%+32.29%$10.3K-2.74%—Stalk
Aug 11, 2023SellARVNRonald PeckChief Medical Officer1,324$24.39$516.8M-44.80%+32.29%$32.3K-4.23%—Stalk